Laura Rodriguez

Partner at Invivo Capital

Speaker

Partner at Invivo Partners, she joined the firm in 2018. Invivo Partners is a venture capital firm specializing in early-stage life sciences companies. The firm is currently investing from its third fund, with a particular focus on advanced therapies, and recently announced a new fund to invest at the intersection of AI and science.

She serves on the Board of Directors of OneChain, Telomere Therapeutics, Telum Therapeutics, Signadori Bio and Eclova Therapeutics, and previously served on the board of Esobiotec (acquired by AstraZeneca). She is also an observer at Arthex and, Gyala Therapeutics.

Previously, she worked as a Project Manager in the Knowledge Transfer and Innovation Unit at the Research Institute of the Vall d'Hebron Hospital (VHIR) in Barcelona.

She has five years of R&D experience in oncology and gene therapy, which has led to publications in peer-reviewed journals and collaborations with biotechnology companies.

She holds a BSc in Biotechnology from the Autonomous University of Barcelona (UAB), a PhD in Biotechnology from the University of Barcelona (UB), and has completed a postgraduate course in Innovation Management at UAB.